Nonclinical evaluation of HBG1/2 and BCL11A as genome editing targets for the treatment of β-hemoglobinopathies
Blood Adv
.
2024 Dec 5:bloodadvances.2024014040.
doi: 10.1182/bloodadvances.2024014040.
Online ahead of print.
Authors
Tusneem Janoudi
1
,
Mrunali Jagdale
1
,
Meng Wu
1
,
Sanjana Gorlla
1
,
Peisheng Zhang
1
,
Ying Shao
1
,
Li Li
1
,
Sheryl R Bowley
1
,
Eugenio Marco
1
,
Kai-Hsin Chang
1
Affiliation
1
Editas Medicine Inc, Cambridge, Massachusetts, United States.
PMID:
39637306
DOI:
10.1182/bloodadvances.2024014040
No abstract available